Healthcare Holding B.V. Gilde Sells 20,516 Shares of Shoulder Innovations (NYSE:SI) Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 20,516 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $22.61, for a total transaction of $463,866.76. Following the transaction, the insider owned 2,187,791 shares of the company’s stock, valued at approximately $49,465,954.51. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Monday, August 24th, Healthcare Holding B.V. Gilde sold 681 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.62, for a total transaction of $15,404.22.
• On Thursday, August 20th, Healthcare Holding B.V. Gilde sold 3,900 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.60, for a total transaction of $88,140.00.
• On Thursday, August 6th, Healthcare Holding B.V. Gilde sold 2,095 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.60, for a total transaction of $47,347.00.
• On Wednesday, August 5th, Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.64, for a total transaction of $166,132.32.
• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.77, for a total value of $2,272,719.24.
• On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.71, for a total value of $244,155.21.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.73, for a total value of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The stock was sold at an average price of $23.36, for a total value of $659,803.20.

Shoulder Innovations Trading Down 0.0%

Shares of NYSE SI opened at $22.21 on Wednesday. Shoulder Innovations, Inc. has a 12 month low of $10.92 and a 12 month high of $24.59. The company has a market cap of $462.41 million and a price-to-earnings ratio of -11.57. The company has a quick ratio of 8.92, a current ratio of 10.71 and a debt-to-equity ratio of 0.12. The business has a fifty day simple moving average of $21.10 and a 200-day simple moving average of $16.66.

Shoulder Innovations (NYSE:SI) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). The company had revenue of $17.18 million during the quarter. Shoulder Innovations had a negative return on equity of 23.61% and a negative net margin of 58.33%. Sell-side analysts predict that Shoulder Innovations, Inc. will post -1.9 EPS for the current year.

Analyst Upgrades and Downgrades

SI has been the topic of a number of recent analyst reports. Piper Sandler restated an “overweight” rating and set a $25.00 price target (up from $19.00) on shares of Shoulder Innovations in a report on Friday, August 7th. UBS Group lifted their price objective on shares of Shoulder Innovations from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. BTIG Research boosted their target price on shares of Shoulder Innovations from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Weiss Ratings upgraded Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Shoulder Innovations currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Compass Financial Management LLC acquired a new position in Shoulder Innovations in the 2nd quarter worth about $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Shoulder Innovations in the third quarter valued at approximately $28,000. California State Teachers Retirement System grew its position in Shoulder Innovations by 412.4% in the second quarter. California State Teachers Retirement System now owns 2,941 shares of the company’s stock worth $60,000 after acquiring an additional 2,367 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of Shoulder Innovations during the 3rd quarter worth $54,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Shoulder Innovations by 66.3% during the 4th quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock valued at $75,000 after purchasing an additional 2,094 shares in the last quarter.

Shoulder Innovations Company Profile

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.